Plus Therapeutics (NASDAQ:PSTV) Given New $65.00 Price Target at Ascendiant Capital Markets

Plus Therapeutics (NASDAQ:PSTV) had its price target reduced by Ascendiant Capital Markets from $475.00 to $65.00 in a report issued on Thursday morning,Benzinga reports. Ascendiant Capital Markets currently has a buy rating on the stock.

A number of other equities research analysts also recently issued reports on the stock. D. Boral Capital reiterated a “hold” rating on shares of Plus Therapeutics in a research report on Tuesday, March 31st. Weiss Ratings restated a “sell (e+)” rating on shares of Plus Therapeutics in a research report on Thursday, January 22nd. Wall Street Zen upgraded Plus Therapeutics to a “sell” rating in a research report on Saturday, April 4th. Lake Street Capital assumed coverage on Plus Therapeutics in a research report on Tuesday, February 3rd. They set a “buy” rating and a $50.00 price objective for the company. Finally, HC Wainwright restated a “buy” rating and set a $25.00 price objective (down from $50.00) on shares of Plus Therapeutics in a research report on Friday, January 23rd. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Plus Therapeutics has an average rating of “Hold” and an average target price of $58.00.

Plus Therapeutics Trading Up 23.7%

PSTV stock opened at $3.92 on Thursday. The firm has a 50 day moving average of $6.19 and a 200-day moving average of $11.15. Plus Therapeutics has a 12-month low of $2.90 and a 12-month high of $30.50. The company has a market cap of $26.89 million, a price-to-earnings ratio of -0.13 and a beta of 1.03.

Plus Therapeutics (NASDAQ:PSTV) last posted its quarterly earnings results on Thursday, March 12th. The company reported $6.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $6.28. The company had revenue of $1.37 million for the quarter, compared to analyst estimates of $1.23 million. Sell-side analysts forecast that Plus Therapeutics will post -2.3 earnings per share for the current fiscal year.

Institutional Trading of Plus Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Susquehanna International Group LLP purchased a new stake in Plus Therapeutics in the 3rd quarter worth approximately $46,000. Jane Street Group LLC purchased a new stake in shares of Plus Therapeutics during the 2nd quarter valued at $41,000. Scientech Research LLC purchased a new stake in shares of Plus Therapeutics during the 3rd quarter valued at $100,000. XTX Topco Ltd purchased a new stake in shares of Plus Therapeutics during the 4th quarter valued at $127,000. Finally, State Street Corp grew its stake in shares of Plus Therapeutics by 37.1% during the 4th quarter. State Street Corp now owns 468,893 shares of the company’s stock valued at $240,000 after buying an additional 127,000 shares during the period. 3.28% of the stock is owned by hedge funds and other institutional investors.

Plus Therapeutics Company Profile

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.